Frontiers in Cell and Developmental Biology,
Journal Year:
2023,
Volume and Issue:
11
Published: Jan. 16, 2023
The
physiopathology
and
neurotransmission
of
pain
are
an
owe
inspiring
complexity.
Our
ability
to
satisfactorily
suppress
neuropathic
or
other
forms
chronic
is
limited.
number
pharmacodynamically
distinct
clinically
available
medications
low
the
successes
achieved
modest.
Pain
Medicine
practitioners
confronted
with
ethical
dichotomy
imposed
by
Hippocrates:
On
one
hand
mandate
primum
non
nocere
,
on
hand,
promise
heavenly
joys
if
successful
divinum
est
opus
sedare
dolorem
.
We
briefly
summarize
concepts
associated
nociceptive
from
input
(afferents
periphery),
modulatory
output
[descending
noradrenergic
(NE)
serotoninergic
(5-HT)
fibers]
local
control.
control
comprised
“
inflammatory
soup
”
at
site
origin
synaptic
relay
stations,
ATP-rich
environment
promoting
inflammation
nociception
while
adenosine-rich
having
opposite
effect.
Subsequently,
we
address
transition
nociceptor
(independent
activation)
process
sensitization
chronification
(transient
progressing
into
persistent
pain).
Having
sketched
a
model
perception
processing
attempt
identify
sites
modes
action
drugs
used
in
treatment,
focusing
adjuvant
(co-analgesic)
medication.
Journal of Clinical Medicine,
Journal Year:
2024,
Volume and Issue:
13(2), P. 403 - 403
Published: Jan. 11, 2024
Limitations
of
pharmaceutical
drugs
and
biologics
for
chronic
diseases
(e.g.,
medication
non-adherence,
adverse
effects,
toxicity,
or
inadequate
efficacy)
can
be
mitigated
by
mobile
medical
apps,
known
as
digital
therapeutics
(DTx).
Authorization
adjunct
DTx
the
US
Food
Drug
Administration
draft
guidelines
on
“prescription
drug
use-related
software”
illustrate
opportunities
to
create
+
combination
therapies,
ultimately
leading
towards
drug–device
products
(DTx
has
a
status
devices).
Digital
interventions
(mobile,
web-based,
virtual
reality,
video
game
applications)
demonstrate
clinically
meaningful
benefits
people
living
with
Alzheimer’s
disease,
dementia,
rheumatoid
arthritis,
cancer,
pain,
epilepsy,
depression,
anxiety.
In
respective
animal
disease
models,
preclinical
studies
environmental
enrichment
other
non-pharmacological
modalities
(physical
activity,
social
interactions,
learning,
music)
surrogates
“active
ingredients”
also
show
improved
outcomes.
this
narrative
review,
we
discuss
how
therapies
impact
translational
research,
discovery
development,
generic
repurposing,
gene
therapies.
Market-driven
incentives
are
illustrated
Humira®
(adalimumab)
facing
“patent-cliff”
competition
cheaper
more
effective
biosimilars
seamlessly
integrated
DTx.
conclusion,
pharma
biotech
companies,
patients,
healthcare
professionals
will
benefit
from
accelerating
integration
pharmacotherapies.
Immunological Reviews,
Journal Year:
2023,
Volume and Issue:
321(1), P. 33 - 51
Published: Sept. 8, 2023
Summary
Neuropathic
pain
is
a
common
and
debilitating
modality
of
chronic
induced
by
lesion
or
disease
the
somatosensory
nervous
system.
Albeit
elucidation
numerous
pathophysiological
mechanisms
development
potential
treatment
compounds,
safe
reliable
therapies
neuropathic
remain
poor.
Multiple
stress/cell
death
pathways
have
been
shown
to
be
implicated
in
neuroinflammation
during
pain.
Here,
we
summarize
current
knowledge
present
an
overview
roles
molecular
pain,
covering
intrinsic
extrinsic
apoptosis,
autophagy,
mitophagy,
ferroptosis,
pyroptosis,
necroptosis,
phagoptosis.
Small
molecule
compounds
that
modulate
alleviating
are
discussed
mainly
based
on
preclinical
models.
These
findings
will
contribute
in‐depth
understanding
pathological
processes
as
well
bridge
gap
between
basic
translational
research
uncover
new
neuroprotective
interventions.
Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
15(7), P. 1799 - 1799
Published: June 23, 2023
Neuropathic
pain
is
a
debilitating
condition
characterized
by
abnormal
signaling
within
the
nervous
system,
resulting
in
persistent
and
often
intense
sensations
of
pain.
It
can
arise
from
various
causes,
including
traumatic
nerve
injury,
neuropathy,
certain
diseases.
We
present
an
overview
current
emerging
pharmacotherapies
for
neuropathic
pain,
focusing
on
novel
drug
targets
potential
therapeutic
agents.
Current
pharmacotherapies,
tricyclic
antidepressants,
gabapentinoids,
serotonin
norepinephrine
re-uptake
inhibitors,
are
discussed,
as
treatments,
such
ambroxol,
cannabidiol,
N-acetyl-L-cysteine.
Additionally,
article
highlights
need
further
research
this
field
to
identify
new
develop
more
effective
targeted
therapies
management.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(8), P. 1068 - 1068
Published: Aug. 15, 2024
Neuropathic
pain,
a
chronic
condition
resulting
from
nerve
injury
or
dysfunction,
presents
significant
therapeutic
challenges
and
is
closely
associated
with
oxidative
stress
inflammation,
both
of
which
can
lead
to
mitochondrial
dysfunction.
The
nuclear
factor
erythroid
2-related
2
(Nrf2)
pathway,
critical
cellular
defense
mechanism
against
stress,
has
emerged
as
promising
target
for
neuropathic
pain
management.
Nrf2
modulators
enhance
the
expression
antioxidant
cytoprotective
genes,
thereby
reducing
damage,
impairment.
This
review
explores
antinociceptive
effects
Nrf2,
highlighting
how
pharmacological
agents
natural
compounds
may
be
used
potential
strategies
pain.
Although
preclinical
studies
demonstrate
reduction
improved
function
through
activation,
several
clinical
need
addressed.
However,
emerging
evidence
suggests
benefits
in
conditions,
such
diabetic
neuropathy
multiple
sclerosis.
Future
research
should
focus
on
further
elucidating
molecular
role
optimize
its
modulation
efficacy
maximize
utility.
Cells,
Journal Year:
2024,
Volume and Issue:
13(22), P. 1857 - 1857
Published: Nov. 8, 2024
Glucagon-like
peptide
1
(GLP-1)
receptor
agonists
are
frequently
used
to
treat
type
2
diabetes
and
obesity.
Despite
the
development
of
several
drugs
for
neuropathic
pain
management,
their
poor
efficacy,
tolerance,
addiction
potential,
side
effects
limit
usage.
Teneligliptin,
a
DPP-4
inhibitor,
has
been
shown
reduce
spinal
astrocyte
activation
caused
by
partial
sciatic
nerve
transection.
Additionally,
we
showed
its
capacity
improve
analgesic
morphine
tolerance.
Recent
studies
indicate
that
GLP-1
synthesized
in
brain
activates
signaling
pathways,
essential
neuroprotection
anti-inflammatory
effects.
Multiple
vitro
vivo
using
preclinical
models
neurodegenerative
disorders
have
properties
associated
with
glucagon-like
peptide-1
(GLP-1R)
activation.
This
study
aimed
investigate
mechanism
antinociception
agonist
semaglutide
(SEMA)
on
diabetic
rats.
